Enhanced in vivo tumour response from Combination Carboplatin and Low Dose c-myc Antisense Oligonucleotides.

Todd Walker, Crispin Dass, Mark Burton

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


BACKGROUND: Phosphorothioate oligonucleotides ([S]ODNs) contain a modified phosphate backbone. Antisense [S]ODNs targeted to specific oncogenes have been used to varying success in vivo. Carboplatin is a commonly used chemotherapeutic and is associated with chemoresistance in some human tumours. The potential for combined antisense [S]ODNs and carboplatin chemotherapy has only recently been explored in vivo. MATERIALS AND METHODS: This study examines the effect of c-myc antisense oligomers delivered in isolation as naked DNA and in combination with carboplatin upon the growth kinetics of an in vivo transplantable adenocarcinoma using rodents. RESULTS: Tumours treated with a combination of 600 microg of 15-mer c-myc phosphorothioate antisense oligodeoxyribonucleotide and an intravenous administration of carboplatin (3 mg/kg), demonstrated a significant (p<0.05) retardation in tumour growth kinetics relative to a control. Two mismatch antisense controls did not significantly inhibit tumour growth. C-myc protein studies in tumour sections failed to show significant differences in c-myc expression in any of the treated tumours. CONCLUSION: This study demonstrates that carboplatin affects the relative abundance of c-myc and that combination treatment of carboplatin and c-myc phosphorothioate antisense oligonucleotides in vivo results in synergistic tumour retardation.
Original languageEnglish
Pages (from-to)2237-2245
Number of pages9
JournalAnticancer Research
Issue number4
Publication statusPublished - 2002


Dive into the research topics of 'Enhanced in vivo tumour response from Combination Carboplatin and Low Dose c-myc Antisense Oligonucleotides.'. Together they form a unique fingerprint.

Cite this